Albumin was more likely to be administered to patients with more severe illness and greater medical complexity, as indicated by higher Model for End-Stage Liver Disease-Sodium (MELD-Na) scores, advanced stages of AKI, and increased rates of cirrhosis complications. This evidence concerns the gene ALB and Cirrhosis.